Diplomat Selected to Dispense CALQUENCE® for Previously-Treated Mantle Cell Lymphoma


The nation's largest independent provider of specialty pharmacy services has been selected as a limited distributor for CALQUENCE® (acalabrutinib)

FLINT, Mich., Nov. 1, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) has been named to the limited pharmacy panel to dispense CALQUENCE® (acalabrutinib).

Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.)

CALQUENCE, recently granted accelerated approval by the Food and Drug Administration, is indicated to treat mantle cell lymphoma (MCL)—a type of non-Hodgkin lymphoma—in adult patients who have received at least one prior therapy.

The average age at MCL diagnosis is the mid-60s, according to the Leukemia & Lymphoma Society.

"CALQUENCE is a needed alternative to treat a life-threatening blood cancer for patients who might not be responding to therapy or whose cancer has relapsed," said Joel Saban, Diplomat president.

To learn more about Diplomat's oncology program, visit diplomat.is/oncology.

CALQUENCE was developed by Acerta Pharma, LLC, a member of the AstraZeneca Group. For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-selected-to-dispense-calquence-for-previously-treated-mantle-cell-lymphoma-300547796.html

SOURCE Diplomat Pharmacy, Inc.


-1.32 -6.46% $ 19.12 Volume: 1,151,451 Common Stock | 20 minute delay September 24, 2018

Investor Contact

Terri Anne Powers,
Vice President, Investor Relations
Diplomat Pharmacy Inc.
Phone: 312.889.5244

Email Now